Although BCR-ABL is not a CK2 phosphorylation substrate, it was found that CX-4945 abrogates the CK2/BCR-ABL interaction and, most importantly, contributes to overcoming imatinib-resistance in different CML cell lines [49]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.